51.591.40% ( -0.73 )
Delay Closed: Nov 17, 15:00:00Valuation
Current ValuationThe current P/E ratio is 42.76, within the reasonable range, cheaper than 25.22% of the time in the past 3 years, and the industry ranks 5/27, the industry Median 46.47.
42.76xP/E
¥51.59Stock price
¥1.21Earnings per share
42.76xP/E
Stock price¥51.59Earnings per share¥1.21
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 37.18x
- Typical range
- 30.65x–44.22x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 46.47x
012243648
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 46.47x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
300759SZPharmaron | 42.45x | 15.50% | ¥75.14B |
688758SHSepax Technologies | 46.47x | -- | ¥9.21B |
688315SHNovogene | 48.11x | 13.01% | ¥7.23B |
301333SZR&G Pharma | 42.76x | 20.98% | ¥4.98B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
